Lectin Mediated Biorecognition as a Novel Strategy for Targeted Delivery to Bladder Cancer
Authors:
- 1 October 2011
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 186 (4) , 1481-1488
Abstract
Inadequate urothelial delivery of drugs is considered a primary cause of current shortcomings in adjuvant intravesical chemotherapy for bladder cancer. We report what is to our knowledge a novel biorecognitive approach to achieve more regionally selective targeting of malignant tissue and improve urothelial uptake based on specific interaction between lectins and bladder cell glycocalyces. We assessed the cytoadhesive and cytoinvasive potential of selected plant lectins in 3 human urothelial cell lines, corresponding to healthy tissue, and low and high grade carcinoma, respectively. Flow cytometry and fluorimetry were used to determine binding capacity and specificity in single cells and confluent monolayers. Monensin quenching experiments, microscopic analysis and enzyme treatment allowed further characterization of internalization, the uptake pathway and the potential cause of tumor selectivity. Wheat germ agglutinin had the highest bioadhesive potential while peanut agglutinin was the most potent discriminator between healthy and cancerous tissue (p <0.01). In each case cell interaction was highly specific (greater than 80%) and proved decisive for efficient uptake. Within 60 minutes after exposure greater than 50% of membrane bound lectins were internalized in acidic compartments. Cancer associated aberrant glycosylation likely represents the determining cause of peanut agglutinin selectivity. Given careful choice of the targeting ligand, the development of carbohydrate based delivery strategies for bladder cancer therapy seems feasible. Lectin bioadhesion may not only mediate preferential accumulation in malignant tissue but also promote cellular internalization via increased recruitment of membrane bound material to physiological uptake routes.Keywords
This publication has 28 references indexed in Scilit:
- BCAN Think Tank session 3: Prevention of bladder cancerUrologic Oncology: Seminars and Original Investigations, 2010
- Bladder Cancer: Narrowing the Gap Between Evidence and PracticeJournal of Clinical Oncology, 2009
- Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment StrategyEuropean Urology, 2009
- Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?BJU International, 2009
- Economic aspects of bladder cancer: what are the benefits and costs?World Journal of Urology, 2009
- Bladder CancerJournal of the National Comprehensive Cancer Network, 2009
- Intravesical Pharmacotherapy for Non–Muscle-Invasive Bladder Cancer: A Critical Analysis of Currently Available Drugs, Treatment Schedules, and Long-Term ResultsEuropean Urology, 2008
- Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, 2007
- Improving Efficacy of Intravesical ChemotherapyEuropean Urology, 2006
- Complications of Intravesical Therapy for Urothelial Cancer of the BladderJournal of Urology, 2006